-
Nat Comm . . . Chen's team reveals the mechanism by which human intestinal microbiome disorders contribute to the onset of intracranial aneurysms and provides new intervention strategies.
Time of Update: 2020-07-18
the results showed that exogenous taurine supplementation after transplantation significantly reduced the overall incidence of intracranial aneurysms compared with mice transplanted with faeces from patients with aneurysms.
-
New Discovery: Obesity is a delay again! Large retrospective analysis showed that chemotherapy was poor in obese breast cancer patients.
Time of Update: 2020-07-18
based on a retrospective analysis of data from large clinical trials, an international team of researchers concluded that overweight or obese breast cancer patients are much less effective than ordinary patients receiving docetaxel, one of the most widely used chemotherapy drugs in the world.
-
The fourth generation of ALK inhibitor TPX-0131 made a stunning debut.
Time of Update: 2020-07-18
Tpx-0131 is the most effective inhibitor for a series of EML4-ALK compound mutations, while the 1st, 2nd and 3rd generation ALK drugs show lower activity and sensitivity (Table 3).
-
The study of pancreatic cancer, which is slow to progress, has seen a major update in the guidelines. CSCO guide!
Time of Update: 2020-07-18
Table 3 treatment principles of metastatic pancreatic cancer, chemotherapy combined with electric field therapy was added in the recommendation of grade III experts, and the update was based on the phase II PANOVA study.
-
Nat Cancer . . . The Yu Huiyong research group found a new mechanism for regulating the reprogramming of liver cancer metabolism.
Time of Update: 2020-07-18
on July 6, 2020, the research group of Yin Huiyong, Shanghai Institute of nutrition and health, Chinese Academy of Sciences, published the latest research results of aldolase B suppresses heparocellular carcinogenesis by inhibiting G6PD and pentose phosphate pathways online in nature cancer, The role, mechanism and clinical significance of 6-bis-phosphate (FBP) aldolase B (aldob) in the regulation of metabolic reprogramming in hepatocellular carcinoma.
-
Best CP! There is a new breakthrough in the treatment of advanced gastric cancer in the combination of "k drug and lunvalitini".
Time of Update: 2020-07-18
recently, the Lancet Oncology published a phase II clinical study on the efficacy and safety of the combination in patients with advanced gastric cancer and esophageal gastric junction adenocarcinoma (epoc1706).
-
Bladder cancer hit! Merck/Pfizer Bavencio's first-line maintenance therapy is approved by the U.S. FDA, significantly extending survival!
Time of Update: 2020-07-18
, July 01, 2020 / PRNewswire/ -- Merck KGaA and partner Pfizer have jointly announced that the U.S Food and Drug Administration ( FDA ) has approved anti-PD-L1 therapy Baven (avelumab) for the m
-
Nat Genetics . . . Zhang's/Liu Yu team worked to develop a non-coding mutation analysis method for individualized tumors for individual cases.
Time of Update: 2020-07-18
98% of the human genome is noncoding, and more than 80% of the noncoding genome contains DNA functional elements (such as promoters, enhancers, etc.), which have the function of gene transcription reg
-
Lung scale cancer heart encapsulation fluid, where to go from? Look at immunotherapy and fight and go.
Time of Update: 2020-07-18
Evaluation of curative effect: chest CT examination on June 25, 2019: after left lung cancer surgery, compared with 2019-5-0-30, some nodules in right lower lobe of lung slightly reduced, pericardial effusion.
-
Physician's Journal Morning Post: IS PSA typical of overdiagnosis and overtreatment?
Time of Update: 2020-07-18
for example, in ERSPC, the cumulative incidence rate of prostate cancer in the screening group was 13.3% in the 16 years, and 10.3% in the control group, and the relative risk of prostate cancer diagnosed in the screening group decreased compared with the control group with the longer follow-up time.
-
Local advanced esophageal cancer: comparison between proton beam therapy and in vitro radiation therapy.
Time of Update: 2020-07-18
to determine whether the use of proton beam radiation therapy instead of conventional external radiotherapy can reduce the toxicity of radiotherapy and chemotherapy without affecting the efficacy, a multicenter, randomized, phase 2 trial involving 107 patients with locally advanced esophageal cancer (median age, 67 years) was conducted.
-
HCC risk prediction model for patients with chronic hepatitis B - The Hope of Precision Medicine- A review of high scores.
Time of Update: 2020-07-18
In the past 10 years, more than 12 risk scoring models have been developed to predict the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). these scoring models divide
-
Based on immunology analysis of tumor distype, this idea is worth learning from!
Time of Update: 2020-07-18
The results showed that: (1) identification and validation of immune subtypes of diffuse low-grade gliomas, based on 782 previously reported immune related genes, the authors used consensus clustering method to identify the immune subtypes of diffuse low-grade gliomas The data sets of 402 diffuse LGG samples were clustered (50 iterations, 80% resampling rate).
-
TIGIT Target - Development.
Time of Update: 2020-07-18
and a phase III clinical trial of tiragolumab, skyscraper-02 (nct04256421), aims to detect whether the increase of tiragolumab has an effect on the treatment of extensive stage small cell lung cancer (first-line) on the basis of atezolizumab combined with chemotherapy.
-
Comprehensive analysis of molecular and clinical characteristics of 1000 children with low-grade glioma.
Time of Update: 2020-07-18
Children with low-grade gliomas (pLGG) are children with a common brain tumor, accounting for about 30% Unlike adult symitomas, which occur primarily in the hemisphere of the brain and inevitably turn
-
U.S. scientists have discovered a specific site of dna methylation imbalance that is the key to cancer.
Time of Update: 2020-07-18
the title is "allele specific DNA methylation is increased in cancers and its dense mapping in normal plus neoplastic cells increases the yield of disease associated regulation By sequencing and analyzing the entire genome of cancer and healthy tissues, researchers have discovered the key to cancer and other disease risks: specific sites in DNA with imbalanced methylation.
-
"2020 POST ASCO" Seminar on the Latest Progress in Lymphoma successfully concluded!
Time of Update: 2020-07-18
topic 6: progress in the treatment of mantle cell lymphoma Professor Zhang Qingyuan, Affiliated Tumor Hospital of Harbin Medical University, presented a wonderful keynote speech on "progress in the treatment of mantle cell lymphoma (MCL)".
-
Large-scale prospective research analysis shows that if you quit smoking, limit alcohol and eat more garlic, you will not have stomach cancer. You have the final say!
Time of Update: 2020-07-18
previous case-control studies based on Linqu population support that smoking rather than alcohol consumption is a risk factor for gastric cancer.
this large-scale prospective study analysis once again supports smoking as a risk factor for gastric cancer incidence and mortality.
-
JEM: Cracking the mystery of smoking promotes lung cancer cells to get into the brain! Scientists have found that nicotine can alter the properties of small glial cells, making the brain suitable for cancer cells to grow.
Time of Update: 2020-07-18
Picture from pexel.com Their experiments found that nicotine in cigarette smoke can cross the blood-brain barrier and reach the brain, prompting macrophages microglia in the brain to change their phenotypes, increase the secretion of growth promoting factors and chemokines, and promote the formation and development of metastatic foci.
-
China Guide Authoritative Voice - Donafini included in CSCO 'Primary Liver Cancer Diagnosis And Treatment Guide' to receive I-level expert recommendation.
Time of Update: 2020-07-18
it is reported that donafinil has been included and strongly recommended in this CSCO guideline for the diagnosis and treatment of primary liver cancer, which is based on the excellent results of the multicenter ll / ll phase clinical study (zgdh3 trial) of donafinil and sorafenib in the first-line treatment of advanced HCC published during the ASCO annual meeting recently.
